Abstract

Current therapeutic regimens for prostate cancer focus on targeting androgen receptor (AR) signaling. However, the AR is a key factor in luminal epithelium differentiation and was shown to have a role as a tumor suppressor. Thus, its inhibition may activate oncogenic pathways that contribute to metastatic castration-resistant prostate cancer (CRPC). Herein, we report a novel tumor promoter, ZBTB46, which is negatively regulated by AR signaling via microRNA (miR)-1-mediated downregulation. ZBTB46 is associated with malignant prostate cancer and is essential for metastasis. Its overexpression can overcome the antitumor effects of miR-1 and promote androgen-independent proliferation. We demonstrated that ZBTB46 can transcriptionally regulate SNAI1, a key epithelial-to-mesenchymal transition (EMT) driver, which could contribute to induction of the EMT after androgen-deprivation therapy and metastasis. Our findings are supportive of the model that disruption of AR's function may predispose prostate cancer to progress to metastatic CRPC.Oncogene advance online publication, 10 July 2017; doi:10.1038/onc.2017.226.

Original languageEnglish
Pages (from-to)6213-6224
JournalOncogene
DOIs
Publication statusE-pub ahead of print - Jul 10 2017

Fingerprint

Androgen Receptors
Carcinogens
Prostatic Neoplasms
Neoplasm Metastasis
Epithelial-Mesenchymal Transition
Castration
MicroRNAs
Androgens
Oncogenes
Publications
Down-Regulation
Epithelium
Therapeutics
Neoplasms

Keywords

  • Journal Article

Cite this

Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis. / Chen, W-Y; Tsai, Y-C; Siu, M K; Yeh, H-L; Chen, C-L; Yin, J J; Huang, J; Liu, Y-N.

In: Oncogene, 10.07.2017, p. 6213-6224.

Research output: Contribution to journalArticle

@article{6f2b337d8547474db9f486f9bfd040c1,
title = "Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis",
abstract = "Current therapeutic regimens for prostate cancer focus on targeting androgen receptor (AR) signaling. However, the AR is a key factor in luminal epithelium differentiation and was shown to have a role as a tumor suppressor. Thus, its inhibition may activate oncogenic pathways that contribute to metastatic castration-resistant prostate cancer (CRPC). Herein, we report a novel tumor promoter, ZBTB46, which is negatively regulated by AR signaling via microRNA (miR)-1-mediated downregulation. ZBTB46 is associated with malignant prostate cancer and is essential for metastasis. Its overexpression can overcome the antitumor effects of miR-1 and promote androgen-independent proliferation. We demonstrated that ZBTB46 can transcriptionally regulate SNAI1, a key epithelial-to-mesenchymal transition (EMT) driver, which could contribute to induction of the EMT after androgen-deprivation therapy and metastasis. Our findings are supportive of the model that disruption of AR's function may predispose prostate cancer to progress to metastatic CRPC.Oncogene advance online publication, 10 July 2017; doi:10.1038/onc.2017.226.",
keywords = "Journal Article",
author = "W-Y Chen and Y-C Tsai and Siu, {M K} and H-L Yeh and C-L Chen and Yin, {J J} and J Huang and Y-N Liu",
year = "2017",
month = "7",
day = "10",
doi = "10.1038/onc.2017.226",
language = "English",
pages = "6213--6224",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis

AU - Chen, W-Y

AU - Tsai, Y-C

AU - Siu, M K

AU - Yeh, H-L

AU - Chen, C-L

AU - Yin, J J

AU - Huang, J

AU - Liu, Y-N

PY - 2017/7/10

Y1 - 2017/7/10

N2 - Current therapeutic regimens for prostate cancer focus on targeting androgen receptor (AR) signaling. However, the AR is a key factor in luminal epithelium differentiation and was shown to have a role as a tumor suppressor. Thus, its inhibition may activate oncogenic pathways that contribute to metastatic castration-resistant prostate cancer (CRPC). Herein, we report a novel tumor promoter, ZBTB46, which is negatively regulated by AR signaling via microRNA (miR)-1-mediated downregulation. ZBTB46 is associated with malignant prostate cancer and is essential for metastasis. Its overexpression can overcome the antitumor effects of miR-1 and promote androgen-independent proliferation. We demonstrated that ZBTB46 can transcriptionally regulate SNAI1, a key epithelial-to-mesenchymal transition (EMT) driver, which could contribute to induction of the EMT after androgen-deprivation therapy and metastasis. Our findings are supportive of the model that disruption of AR's function may predispose prostate cancer to progress to metastatic CRPC.Oncogene advance online publication, 10 July 2017; doi:10.1038/onc.2017.226.

AB - Current therapeutic regimens for prostate cancer focus on targeting androgen receptor (AR) signaling. However, the AR is a key factor in luminal epithelium differentiation and was shown to have a role as a tumor suppressor. Thus, its inhibition may activate oncogenic pathways that contribute to metastatic castration-resistant prostate cancer (CRPC). Herein, we report a novel tumor promoter, ZBTB46, which is negatively regulated by AR signaling via microRNA (miR)-1-mediated downregulation. ZBTB46 is associated with malignant prostate cancer and is essential for metastasis. Its overexpression can overcome the antitumor effects of miR-1 and promote androgen-independent proliferation. We demonstrated that ZBTB46 can transcriptionally regulate SNAI1, a key epithelial-to-mesenchymal transition (EMT) driver, which could contribute to induction of the EMT after androgen-deprivation therapy and metastasis. Our findings are supportive of the model that disruption of AR's function may predispose prostate cancer to progress to metastatic CRPC.Oncogene advance online publication, 10 July 2017; doi:10.1038/onc.2017.226.

KW - Journal Article

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85033446415&origin=resultslist&sort=plf-f&src=s&sid=fdb2a8c9f8b8d7d92f0adf9ce2281f85&sot=a&sdt=a&sl=18&s=AU-ID%2856239890100%29&relpos=3&citeCnt=2&searchTerm=#

UR - https://www.scopus.com/results/citedbyresults.uri?sort=plf-f&cite=2-s2.0-85033446415&src=s&imp=t&sid=a2a49af2edb5779f514b031b82db25a8&sot=cite&sdt=a&sl=0&origin=recordpage&editSaveSearch=&txGid=9eb1ffd610e7a57809608358007f157c

U2 - 10.1038/onc.2017.226

DO - 10.1038/onc.2017.226

M3 - Article

C2 - 28692046

SP - 6213

EP - 6224

JO - Oncogene

JF - Oncogene

SN - 0950-9232

ER -